NCT03856216 2025-10-16
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
12 trialsNCT02100891 2025-03-19
STIR
Medical College of Wisconsin
Phase 2 Terminated
NCT02995330 2024-02-13
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT00176930 2021-01-22
Stem Cell Transplant for Hematological Malignancy
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT00303719 2020-05-12
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01588951 2018-08-14
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2/3 Terminated
NCT00176839 2017-12-05
Stem Cell Transplantation for Hematological Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2/3 Terminated
NCT00003926 2017-11-29
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00005984 2017-11-29
Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00593645 2014-09-12
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
Washington University School of Medicine
Phase 2 Terminated
NCT00499889 2012-04-23
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
M.D. Anderson Cancer Center
Phase 2 Terminated